In contrast to lung cancer, EGFR inhibitors have not shown a significant efficacy in bladder cancer patients; therefore, it is urgent to develop a novel therapeutic strategy to improve the effectiveness of EGFR inhibitors in bladder cancer treatment [5]. This evidence concerns the gene EGFR and lung carcinoma.